Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns

Table 5

OCR/DCR of patients with soft tissue sarcoma using different treatment methods.

Treatment	Anlotinib	Anlotinib plus chemotherapy	Anlotinib plus radiotherapy	Total
First line (OCR and DRR)	100 (1/1), 100 (1/1)	50 (3/6), 100 (6/6)	0 (0/1), 100 (1/1)	50 (4/8), 100 (8/8)
Second line (OCR and DRR)	0 (0/12), 67 (8/12)	33 (2/6), 50 (3/6)	0 (0/0), 0 (0/0)	11 (2/18), 61 (11/18)
Beyond second line (OCR and DRR)	0 (0/3), 100 (3/3)	0 (0/1), 0 (0/1)	0 (0/1), 0 (0/1)	0 (0/5), 60 (3/5)
Total	6 (1/16), 75 (12/16)	38 (5/13), 69 (9/13)	0 (0/2), 50 (1/2)	19 (6/31), 71 (22/31)